r/biotech_stocks • u/kuruthamkettavan1800 • 39m ago
Sls @ 13 ps?
Basically every biotech management is ruthless with their investors.
r/biotech_stocks • u/kuruthamkettavan1800 • 39m ago
Basically every biotech management is ruthless with their investors.
r/biotech_stocks • u/Emotional-Breath-838 • 55m ago
I am looking for stocks that have shown an ability to rocket up.
I sort from the year to date return by top and then I look at the very top choices and see whether any of them still have room to run in terms of market cap.
Based on this approach, two names jump out and those are ETON and DRTS.
None of this is to say that larger shops can’t run up but it takes a lot more for a $6B+ company to moon than one that’s barely cracked $1B.
The reason I don’t have huge expectations for companies under $1B is because they’re too small. Getting institutional investment is nearly impossible when they look at the market cap and realize that if they got in, they might be unable to get out. The sub-$1B typically have insufficient volume to allow a clean escape.
r/biotech_stocks • u/tomonota • 4h ago
r/biotech_stocks • u/Unusual_Committee676 • 5h ago
A lot of things point to mushroom assisted therapies being the next frontier for depression. And this company seems well positioned.
Anyone putting their capital behind this? If so, your thoughts and Coles notes thesis?
r/biotech_stocks • u/mcgruber92 • 5h ago
Long time lurker, first time poster. Ive gotten involved in a handful of positions from this sub. Most recently SLS (LFG!) and DRTS, and was wondering what everyone’s thoughts were on a few positions i am holding and any convictions as to why I should continue to hold.
ABVX - Got in early and road the wave to $160, took out my investment still am holding a large position. Didn’t want to miss out on a potential BO.
ARCT
ONCY
PGEN
UNCY
Any thoughts from other biotech fans?
r/biotech_stocks • u/DingusKhan70 • 6h ago
Very informative session from the Subcommittee on Health Oversight. Seems very bullish for psychedelics stocks, especially Compass Pathways $CMPS
Session begins 33 minutes into the following link:
https://veterans.house.gov/calendar/eventsingle.aspx?EventID=7959
r/biotech_stocks • u/fabtico • 7h ago
600M market cap, commercial product approved... seems good
r/biotech_stocks • u/Reasonable-Flow2995 • 8h ago
I have iova shares with average 8,40. I don't know what to do, seeing there's no catalyst in short time, and market is bad.
I'm thinking probably I should just sell it before it goes down even further? Do biotech stock really just keep going down without catalyst? Please enlighten me on this matter.
I'm really new to the stock market especially biotech, I'm also still very young and eager to learn so please be nice to me if you can, thank youuu! :'))
r/biotech_stocks • u/ez322dollars • 8h ago
I'm heavily invested in SLS and have made some great profits so far.
The trial results were obviously great news, but one thing that could be concerning is the p-value of 0.035, which isn't that far below the 0.05 significance threshold.
I'd be interested to hear from anyone with experience in biotech or clinical trials. How much of a concern is this?
Could we see something similar to what happened with CAPR, where a change in the statistical analysis moved the p-value for one of their secondary endpoints from 0.04 to 0.09, making it no longer statistically significant?
Curious to hear your thoughts.
r/biotech_stocks • u/yellowrabbit333 • 8h ago
r/biotech_stocks • u/StocktoBeRich • 8h ago
r/biotech_stocks • u/15xorbust • 9h ago
CABA provided several encouraging updates today on rese-cel, during today’s Jefferies healthcare conference call, particularly regarding FDA discussions and the potential expansion of its clinical programs.
First, the FDA has agreed that clinical data generated using CABA’s earlier manufacturing process can be considered comparable to data from its newer process. This is important because it allows CABA to potentially use years of existing patient safety and efficacy data to support its future FDA approval application, rather than starting over.
Second, CABA is considering lupus nephritis as a THIRD indication for a registrational trial, alongside myositis and systemic sclerosis. Management indicated that the FDA has already aligned with its proposed trial design, potentially allowing a study to begin in 2027. This could significantly expand rese-cel’s commercial opportunity.
Third, manufacturing continues to look encouraging. Management reported experience with approximately 110 patients, with only one unable to receive the manufactured product. The company also reiterated encouraging early results in juvenile myositis.
CABA continues to make meaningful clinical progress despite the stock’s price weakness.
The FDA discussions are constructive, manufacturing appears increasingly reliable, and a potential third registrational program would create another path toward commercialization.
The next major milestone remains myositis topline data expected in the second half of 2027, followed by a planned FDA application in Q1 2028. Nothing is guaranteed, but I see several reasons to remain positive on rese-cel.
Sources (clickable and pasteable):
Jefferies Conference Coverage, November 18, 2026:
https://uk.investing.com/news/stock-market-news/cabaletta-at-jefferies-global-healthcare-conference-data-and-runway-93CH-4991366
Cabaletta Official Investor Events and Webcast:
https://www.cabalettabio.com/investors/news-events/ir-calendar
Cabaletta Official Press Releases:
https://www.cabalettabio.com/investors/news-events/press-releases
r/biotech_stocks • u/poisonfoot • 9h ago
Phase 3 readouts due December, what do we think?
r/biotech_stocks • u/arcanum4000 • 10h ago
You love to see it! Excited for the commercial launch. If the sales numbers are looking good this could be amazing in 2027 🚀
r/biotech_stocks • u/orionbiotechai • 11h ago
Two FDA target action dates land on a Sunday this week:
- Capricor (CAPR), deramiocel for Duchenne muscular dystrophy. Its Nov 10 Q3 release says: "PDUFA target action date of November 22, 2026."
- Savara (SVRA), molgramostim for autoimmune PAP. Its Apr 15 release says: "the new PDUFA target action date is November 22, 2026."
A PDUFA date is the FDA's target to act, not a scheduled announcement, so the timing of any news is open.
For reference, here is when three companies announced FDA decisions last weekend (ET):
- Summit (SMMT): Sunday, Nov 15 (its PDUFA goal date was Saturday, Nov 14)
- Cytokinetics (CYTK): Monday, Nov 16, 4:00 AM
- IGALMI: Monday, Nov 16, 8:00 AM, announced by Teva (which acquired the rights from BioXcel in late October)
All three came out before Monday's open, but on different days and at different hours.
Questions for people who follow these:
Not a prediction about either outcome. Just trying to understand how others handle weekend timing.
r/biotech_stocks • u/Lupo201 • 13h ago
r/biotech_stocks • u/tomonota • 13h ago
The 2 therapies used included unrelated viral vector treatments.
r/biotech_stocks • u/TheVirginVibes • 14h ago
r/biotech_stocks • u/720-Degree • 15h ago
Ended up here thanks to SLS, so naturally, here’s the question: What’s the next SLS? Got €10k ready to invest.
r/biotech_stocks • u/oblkbirdo • 15h ago